Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Alexion Pharmaceuticals ( ALXN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.1%. By the end of trading, Alexion Pharmaceuticals rose $1.82 (2%) to $93.66 on average volume. Throughout the day, 2.7 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in a price between $91.41-$94.41 after having opened the day at $91.41 as compared to the previous trading day's close of $91.84. Other companies within the Health Care sector that increased today were: Progenics Pharmaceuticals ( PGNX), up 29%, Aoxing Pharmaceutical Company ( AXN), up 12%, Atossa Genetics ( ATOS), up 11.1%, and Idera Pharmaceuticals ( IDRA), up 10.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $17.86 billion and is part of the drugs industry. The company has a P/E ratio of 71.5, above the S&P 500 P/E ratio of 17.7. Shares are down 2% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Supernus Pharmaceuticals ( SUPN), down 19.7%, Albany Molecular Research ( AMRI), down 12.9%, SunLink Health Systems ( SSY), down 11.8%, and ARCA biopharma ( ABIO), down 10.3%, were all laggards within the health care sector with Stryker Corporation ( SYK) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers